Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab QTc study in advanced cancer
NCT01017731Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Primary completion
- Apr 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in solid tumor, sponsored by Eli Lilly and Company. Started Nov 2009; status: completed.
02
Drugs
ramucirumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01017731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01017731.